Tirzepatide

Also known as: Mounjaro · Zepbound

Mechanism of action

Dual agonist of the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. It simultaneously activates both receptors, enhancing insulin secretion, reducing glucagon, suppressing appetite, and promoting energy expenditure.

Reported research ranges

2.5 mg subcutaneously per week (initial), escalating to 15 mg/week.

Reported adverse effects

Nausea, diarrhea, vomiting, constipation. Similar to semaglutide but with greater efficacy.

Storage and handling

Refrigerate at 2–8 °C. Do not freeze.

This material is published for scientific and educational reference. It is not medical advice, not a treatment recommendation, and not an offer to sell. Compounds discussed are for research and laboratory use only.